Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals develops clinical-stage therapies for addiction and related disorders, with its lead investigational product candidate, AD04, focused on alcohol use disorder in heavy drinking patients. News about ADIL commonly centers on AD04 clinical-development planning, FDA-related regulatory discussions, precision-medicine positioning, intellectual property filings, manufacturing and technical-transfer work, and potential commercial pathways for the program.
Company updates also cover financial results, cash runway commentary, Nasdaq listing compliance, and governance or capital-structure actions tied to its public-company status. The recurring business context is a single-segment biopharmaceutical developer advancing a genetically targeted serotonin-3 receptor antagonist approach for alcohol use disorder.
Adial Pharmaceuticals (NASDAQ:ADIL, ADILW) announced its participation in the LD Micro 500 Virtual Investor Conference from September 1-4, 2020. The CEO, William Stilley, will present on September 2 at 3:20 p.m. ET, with a live webcast available. The conference showcases key players in the small and micro-cap sector, featuring one-on-one meetings via video calls. Adial is focused on developing treatments for addictions, particularly its lead product AD04, currently in Phase 3 trials for Alcohol Use Disorder. For more information, visit Adial's website.